|
Convertible Instruments - Additional Information (Detail) (USD $)
|
3 Months Ended | 6 Months Ended | 12 Months Ended | 121 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nov. 30, 2013
|
Nov. 30, 2012
|
Nov. 30, 2013
|
Nov. 30, 2012
|
May 31, 2013
|
Nov. 30, 2013
|
Nov. 30, 2013
Investor
|
May 31, 2013
Investor
|
May 31, 2013
Minimum
|
Nov. 30, 2013
Minimum
Investor
|
May 31, 2013
Minimum
Investor
|
May 31, 2013
Maximum
|
Nov. 30, 2013
Maximum
Investor
|
May 31, 2013
Maximum
Investor
|
Nov. 30, 2013
US Phase III trial
|
Nov. 30, 2013
US new drug application approval by the FDA
|
Nov. 30, 2013
Convertible Note One
Note
|
Nov. 30, 2013
Convertible Note Two
Note
|
Nov. 30, 2013
Convertible Note Three
Note
|
Nov. 30, 2013
Convertible Note Four
|
May 31, 2010
Series B convertible preferred stock
|
Nov. 30, 2013
Series B convertible preferred stock
|
May 31, 2010
Common Stock
|
Apr. 30, 2010
Common Stock
|
|
| Class of Stock [Line Items] | ||||||||||||||||||||||||
| Preferred Stock, Shares issued | 95,100 | 95,100 | 95,100 | 95,100 | 400,000 | |||||||||||||||||||
| Preferred Stock, Share issuance price | $ 1.30 | $ 1.30 | $ 1.30 | $ 5.00 | ||||||||||||||||||||
| Cash proceeds | $ 2,009,000 | |||||||||||||||||||||||
| Preferred stock shares outstanding | 95,100 | 95,100 | 95,100 | 95,100 | 95,100 | |||||||||||||||||||
| Number of common shares issued upon conversion of preferred stock | 10 | |||||||||||||||||||||||
| Convertible note conversion price per share | $ 0.75 | $ 0.65 | $ 0.65 | $ 0.75 | $ 0.50 | |||||||||||||||||||
| Common stock shares authorized for issuance | 100,000,000 | 100,000,000 | 100,000,000 | 100,000,000 | 100,000,000 | |||||||||||||||||||
| Constructive dividend to Preferred stock holders | 6,000,000 | |||||||||||||||||||||||
| Liquidation preference on common shares | 5.00 | 5.00 | 5.00 | |||||||||||||||||||||
| Dividends are payable to preferred stock holders | $ 0.25 | |||||||||||||||||||||||
| Face amount of notes | 1,200,000 | 1,200,000 | 6,588,250 | 1,200,000 | ||||||||||||||||||||
| Convertible note, conversion amount | 4,521,250 | 100,000 | ||||||||||||||||||||||
| Number of notes converted | 6 | 1 | 2 | |||||||||||||||||||||
| Convertible notes term | 6 months | 6 months | 6 months | 3 years | ||||||||||||||||||||
| Principal amount of notes | 2,350,000 | 567,000 | 850,000 | 250,000 | 380,000 | 1,120,000 | ||||||||||||||||||
| Common stock issued upon conversion of notes | 1,307,692 | 594,384 | 1,493,333 | |||||||||||||||||||||
| Warrants to purchase shares of common stock | 659,486 | 292,307 | ||||||||||||||||||||||
| Warrants exercise price per share | 0.75 | 0.75 | 0.75 | 0.50 | 2.00 | 0.75 | 0.75 | |||||||||||||||||
| Aggregate principal amount plus accrued but unpaid interest | 6,351 | |||||||||||||||||||||||
| Exercisable warrants, expire period | 5 years | |||||||||||||||||||||||
| Interest expense associated with conversion inducement | 193,160 | 193,160 | 193,000 | |||||||||||||||||||||
| Earliest date for repayment of principal on remaining notes | Feb. 01, 2014 | |||||||||||||||||||||||
| Latest date for repayment of principal on remaining notes | Mar. 06, 2016 | |||||||||||||||||||||||
| Interest rate on convertible notes | 5.00% | 10.00% | ||||||||||||||||||||||
| Interest on convertible notes payment start date | Apr. 01, 2013 | |||||||||||||||||||||||
| Common stock warrant term | 2 years | 3 years | ||||||||||||||||||||||
| Warrants to purchase common shares, shares | 9,451,056 | |||||||||||||||||||||||
| Amortization expense | $ 1,595,000 | $ 0 | $ 3,047,000 | $ 257,300 | $ 4,756,000 | |||||||||||||||||||